Combined treatment with paxalisib and mirdametinib significantly extends survival of SJ-DIPGX37-bearing mice.
Mr Newby, why is it that you apply one standard regarding NOX use of mouse trials, but don’t apply the same standard to KZA, with reference to the above MOUSE trial posted to the KZA board in July 2021?
- Forums
- ASX - By Stock
- NOX
- Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed, page-21
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
STX
Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
Add NOX (ASX) to my watchlist
|
|||||
Last
6.9¢ |
Change
-0.003(4.17%) |
Mkt cap ! $20.16M |
Open | High | Low | Value | Volume |
6.9¢ | 6.9¢ | 6.9¢ | $3.085K | 44.70K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 22852 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 1310 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 22852 | 0.069 |
1 | 10000 | 0.068 |
2 | 47278 | 0.066 |
1 | 15000 | 0.065 |
2 | 89000 | 0.063 |
Price($) | Vol. | No. |
---|---|---|
0.070 | 1310 | 1 |
0.072 | 1237 | 1 |
0.074 | 50000 | 1 |
0.076 | 4999 | 1 |
0.079 | 12000 | 1 |
Last trade - 15.09pm 02/08/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |